Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

As of October 31, 2024, Adaptimmune Therapeutics plc (NASDAQ:ADAP) experienced a notable decrease in short interest during the month of October. On October 15, the total short interest amounted to 5,560,000 shares, marking an 8.7% decline from the previous total of 6,090,000 shares recorded on September 30. Given the average daily volume of 1,580,000 shares, the current days-to-cover ratio stands at 3.5 days.

Analyst Ratings and Insights

Recent analyses by several research firms have led to varied ratings for ADAP shares. HC Wainwright maintained a "buy" rating and set a price target of $4.00 in a research note published on August 13. Additionally, StockNews.com upgraded Adaptimmune Therapeutics from a "hold" to a "strong-buy" rating on the same date.

Institutional Investor Activity

A number of institutional investors have adjusted their positions in Adaptimmune Therapeutics. Fullcircle Wealth LLC took a new position in the company during Q3, investing approximately $33,000. Vontobel Holding Ltd. increased its holdings in Adaptimmune by 230.8% during the same quarter, now owning 43,000 shares valued at about $41,000 after adding 30,000 shares. Other notable moves include Boulder Hill Capital Management LP, which purchased shares worth $143,000 in the first quarter, and Renaissance Technologies LLC, which raised its stake by 28.3% in Q2. As of now, hedge funds and institutional investors collectively own about 31.37% of Adaptimmune’s stock.

Current Stock Performance

The trading day opened with ADAP shares at $0.70. The company maintains a debt-to-equity ratio of 0.26 and both a current and quick ratio of 3.09. The fifty-day moving average price is currently $0.99, while the two-hundred-day moving average sits at $1.06. Over the past year, the stock has seen a low of $0.42 and a high of $2.05. Adaptimmune Therapeutics holds a market capitalization of $171.99 million, a negative PE ratio of -0.94, and a beta of 2.20.

On August 12, Adaptimmune Therapeutics reported its quarterly earnings, showcasing earnings of $0.27 per share. The company also posted a revenue of $128.23 million for the quarter, significantly exceeding analyst expectations of $58.00 million. However, it had a negative net margin of 51.25% and a negative return on equity of 116.80%. Analysts are predicting an EPS of -0.23 for the current year.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company that specializes in developing innovative cell therapies primarily for cancer patients in the US and UK. Its pipeline includes the SPEARHEAD-1 trial, currently in phase II with ADP-A2M4 for treating synovial sarcoma, as well as SURPASS-3 in phase II with ADP-A2M4CD8 for patients with platinum-resistant ovarian cancer. Additionally, the SURPASS trial is ongoing in phase I involving patients with head and neck and urothelial cancers.

Adaptimmune, Short, Interest